Business Standard
Thursday, May 31, 2012
drived banner
drived banner
  Advanced Search
RSS
Content Guide
Follow us on  
||Companies & Industry||||||| 
 Section Home | News Now | Today's Paper | Q&A | People in the News | Industry News | Features | The Compass | Research & Analysis | Opinion | Corporate Results
Home > Companies & Industry Live Markets | Commodities
 

QVT threatens to block Wockhardt's nutrition biz sale
Press Trust of India / New Delhi Jan 18, 2010, 19:20 IST

The US-based investor fund QVT Advisors today threatened to block debt-ridden Wockhardt's Rs 620-crore sale of nutrition business to Abott, intensifying the fight with the promoters of the drugmaker over a corporate debt restructuring programme.

"We are opposed to the sale of assets of Wockhardt as the promoters are not ready for any dilution of their stake," a QVT spokesperson in India said.

He said Wockhardt had to inform the Bombay High Court before selling the nutrition business and as soon as it informs the court, a group of bond holders led by QVT would file a petition to stop the sale.

Last year Wockhardt had signed a deal to sell its nutrition business, including the Farex brand, to Abott for Rs 620 crore. In separate deal, Wockhardt sold its animal care business to Pfizer for Rs 350 crore.

While deal for the sale of animal care business has been sealed, the nutrition business sales is yet to be completed.

The QVT spokesperson said Wockhardt even took a non-competing fee for selling its animal healthcare business.

The investor fund, however, has offered Wockhardt a new restructuring programme, under which the promoters will be required to issue fresh foreign currency convertible bonds (FCCBs) to cover for the current outstanding of $140 million, from a previous FCCB issued in 2004.

Earlier, QVT had filed a winding up petition in the Bombay High Court after the drug maker defalted in repaying the FCCB issued in 2004 to the investor fund. The court will hear the matter on January 29.

New Ipad Application :Business Standard's all new IPad App
Click here to download for free
Arrow Other Stories     
- Markets languish as heavyweights drag
- Jeera up on spot demand, tight supply
- GMR Infra claims TNEB owes dues of Rs 850 cr
- Turmeric rises on spot demand
- Normal life hit by bandh in Arunachal Pradesh
  Read Business news in 
- India's no. 1 Property Site. Click here to know more
- "Discover The Power of One"
- Help a Child Achieve her. Click to know more
- The Best Seller is Also the No. 1 in Mileage. Click here
- Watch The Film Here. Click here to know more..
- Learn How One City is Running on FOOD SCRAPS.
- 1 billion in saving for Unilever without any tangles.
- A Brand New Server at a Price That Fits Your Budget. Click here
- One Partnership Endless Possibilities. Click here to know more
- Helping doctors detect diseases earlier, saving costs & extending lives.
- Which is the best plan for your daughter
- Check out the TRUE COLOURS of your Stocks, Now for FREE!
- One of the leading business schools in the world.Know More
- 2 Lac Apartments, 1 Lac House / Plots. Click here
Sorry, comments to this story are closed
Latest Messages
Table for Two
  Now available at Special price
  Rs.280/- Only

  Buy Now
BS POLL
UPA 2 has completed three years. How do you rate its performance?  Read the story
  Good
  Average
  Bad
Submit
Most Popular
Read
E-Mailed
Commented
   
- NDA-led bandh turns violent in Bangalore
- Investors wary as Flipkart shows growth pangs
- Army chief slams BEML on Tatra, awards it Rs 1,500-cr deal
- Wealthy clients turned tables on UBS and staff?
- Kingfisher Airlines Q4 loss more than trebles
 
 More  
Tax Shastra
  Now available at Special price
  Rs. 360/- Only

  Buy Now
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring BS Books
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World | General News
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Contact Us